

ASX ANNOUNCEMENT 22 June 2021

COVID-19 VACCINE MANUFACTURING DISCUSSIONS WITH THE VICTORIAN GOVERNMENT AND MONASH INSTITUTE OF PHARMACEUTICAL SCIENCES

IDT Australia Limited (ASX: IDT) provides the following market update.

IDT is progressing discussions with the Victorian Government and mRNA Victoria, along with Monash Institute of Pharmaceutical Sciences in relation to IDT potentially providing cGMP manufacturing services to progress the development of Australia's first local mRNA COVID-19 vaccine candidate.

"Preclinical evaluation of our mRNA vaccine has progressed well and we are now keen to partner with an experienced pharmaceutical manufacturer to produce a product for clinical evaluation. We look forward to working with IDT to establish mRNA vaccine manufacturing capability in Australia" said Professor Colin Pouton of MIPS.

"IDT is progressing discussions to put forward its cGMP manufacturing facilities and capabilities to get behind the Victorian Government's landmark commitment and initiative to develop an mRNA manufacturing capability, as we believe it will build upon the existing scientific and medical strengths in Victoria and will deliver essential capabilities for Australia." said Dr David Sparling, CEO of IDT Australia Limited. "Manufacturing clinic-ready vaccine candidates coming out of world class research such as Professor Pouton's at Monash University allows IDT to develop the critical skills and infrastructure at a sovereign cGMP manufacturing site here in Australia. These capabilities will then be locally available for clinical and commercial applications for COVID-19 as well as a broad range of other diseases."

The Company will provide updates as additional information comes to hand.

Ends..../

IDT

Authorised by the Board of Directors of IDT Australia Limited. For further information please contact:

Dr David Sparling Chief Executive Officer - IDT Australia Limited +61 3 9801 8888

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.